KIAA1755

Summary

KIAA1755 (HGNC:29372) is a protein-coding gene on chromosome 20q11.23, encoding Uncharacterized protein KIAA1755 (Q5JYT7).

Predicted to enable guanyl-nucleotide exchange factor activity. Predicted to be involved in axon guidance. Predicted to be active in cytoplasm and plasma membrane. Predicted to be extrinsic component of membrane.

Source: NCBI Gene 85449 — RefSeq curated summary.

At a glance

• GWAS associations: 33
• Clinical variants (ClinVar): 218 total
• MANE Select transcript: NM_001029864

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29372
Approved symbol	KIAA1755
Name	KIAA1755
Location	20q11.23
Locus type	gene with protein product
Status	Approved
Aliases	RP5-1054A22.3, quo
Ensembl gene	ENSG00000149633
Ensembl biotype	protein_coding
Entrez	85449

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 20 protein_coding, 3 retained_intron

ENST00000279024, ENST00000435901, ENST00000460881, ENST00000484362, ENST00000487506, ENST00000496900, ENST00000611812, ENST00000904202, ENST00000904203, ENST00000904204, ENST00000904205, ENST00000904206, ENST00000904207, ENST00000904208, ENST00000904209, ENST00000904210, ENST00000904211, ENST00000961896, ENST00000961897, ENST00000961898, ENST00000961899, ENST00000961900, ENST00000961901

RefSeq mRNA: 2 — MANE Select: NM_001029864 NM_001029864, NM_001348708

CCDS: CCDS33467

Canonical transcript exons

ENST00000279024 — 14 exons

Exon	Start	End
ENSE00000991701	38225665	38225781
ENSE00000991702	38223538	38223636
ENSE00000991703	38222449	38222597
ENSE00001780141	38210503	38213743
ENSE00003472816	38218244	38218366
ENSE00003603128	38239528	38239725
ENSE00003641266	38219630	38219768
ENSE00003712051	38240582	38241929
ENSE00003736070	38228147	38228240
ENSE00003736267	38245929	38246126
ENSE00003741961	38227154	38227240
ENSE00003753709	38231202	38231325
ENSE00003789140	38217253	38217474
ENSE00003849063	38260498	38260735

Expression profiles

Bgee: expression breadth ubiquitous, 198 present calls, max score 95.13.

FANTOM5 (CAGE): breadth broad, TPM avg 7.6173 / max 403.1750, expressed in 696 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
187244	6.0188	657
187243	1.5272	300
187245	0.0713	22

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	95.13	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	92.29	gold quality
tibial nerve	UBERON:0001323	91.72	gold quality
spinal cord	UBERON:0002240	90.58	gold quality
descending thoracic aorta	UBERON:0002345	90.39	gold quality
endocervix	UBERON:0000458	90.32	gold quality
body of uterus	UBERON:0009853	88.87	gold quality
mucosa of stomach	UBERON:0001199	88.41	gold quality
putamen	UBERON:0001874	88.20	gold quality
thoracic aorta	UBERON:0001515	87.73	gold quality
ascending aorta	UBERON:0001496	87.61	gold quality
right atrium auricular region	UBERON:0006631	87.48	gold quality
tendon of biceps brachii	UBERON:0008188	87.40	gold quality
muscle layer of sigmoid colon	UBERON:0035805	87.28	gold quality
right ovary	UBERON:0002118	86.82	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	86.71	gold quality
substantia nigra	UBERON:0002038	86.68	gold quality
gall bladder	UBERON:0002110	86.58	gold quality
caudate nucleus	UBERON:0001873	86.43	gold quality
cardiac atrium	UBERON:0002081	86.37	gold quality
lower esophagus	UBERON:0013473	86.30	gold quality
lower esophagus muscularis layer	UBERON:0035833	86.30	gold quality
smooth muscle tissue	UBERON:0001135	86.27	gold quality
amygdala	UBERON:0001876	86.24	gold quality
corpus callosum	UBERON:0002336	85.88	gold quality
apex of heart	UBERON:0002098	85.79	gold quality
Brodmann (1909) area 9	UBERON:0013540	85.59	gold quality
endothelial cell	CL:0000115	85.56	gold quality
hypothalamus	UBERON:0001898	85.19	gold quality
midbrain	UBERON:0001891	84.98	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.80
E-MTAB-9543	no	1.22

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

81 targeting KIAA1755, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-4802-3P	99.72	70.13	1273
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-3618	99.69	68.57	1012
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-7150	99.62	66.80	1322
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-516B-5P	99.56	66.33	1495
HSA-MIR-7106-5P	99.53	67.47	3574

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	D630003M21Rik	ENSMUSG00000037813
rattus_norvegicus	Kiaa1755	ENSRNOG00000014424

Paralogs (22): TRIO (ENSG00000038382), MCF2L2 (ENSG00000053524), PLEKHG2 (ENSG00000090924), MCF2 (ENSG00000101977), ARHGEF7 (ENSG00000102606), PLEKHG1 (ENSG00000120278), MCF2L (ENSG00000126217), ARHGEF6 (ENSG00000129675), ARHGEF9 (ENSG00000131089), VAV3 (ENSG00000134215), VAV1 (ENSG00000141968), TIAM2 (ENSG00000146426), PLEKHG4B (ENSG00000153404), TIAM1 (ENSG00000156299), KALRN (ENSG00000160145), VAV2 (ENSG00000160293), ARHGEF40 (ENSG00000165801), SPATA13 (ENSG00000182957), SESTD1 (ENSG00000187231), PLEKHN1 (ENSG00000187583), PLEKHG4 (ENSG00000196155), ARHGEF25 (ENSG00000240771)

Protein

Protein identifiers

Uncharacterized protein KIAA1755 — Q5JYT7 (reviewed: Q5JYT7)

All UniProt accessions (4): Q5JYT7, A0A087WWV7, A0A087X0C1, Q5JYT8

RefSeq proteins (2): NP_001025035, NP_001335637 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR052231	Rho_GEF_signaling-related	Family

UniProt features (17 total): compositionally biased region 6, region of interest 5, sequence variant 5, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5JYT7-F1	64.84	0.36

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 34 (showing top): GOBP_NEUROGENESIS, CCATCCA_MIR432, GOBP_CELL_PROJECTION_ORGANIZATION, chr20q11, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOMF_GUANYL_NUCLEOTIDE_EXCHANGE_FACTOR_ACTIVITY, GOCC_EXTRINSIC_COMPONENT_OF_MEMBRANE, GOMF_NUCLEOSIDE_TRIPHOSPHATASE_REGULATOR_ACTIVITY, GOMF_ENZYME_REGULATOR_ACTIVITY, MEISSNER_NPC_HCP_WITH_H3K4ME2, MIKKELSEN_IPS_HCP_WITH_H3_UNMETHYLATED, GOBP_AXON_DEVELOPMENT, DELACROIX_RAR_BOUND_ES, PEDRIOLI_MIR31_TARGETS_UP, SUPT16H_TARGET_GENES

GO Biological Process (1): axon guidance (GO:0007411)

GO Molecular Function (1): guanyl-nucleotide exchange factor activity (GO:0005085)

GO Cellular Component (3): cytoplasm (GO:0005737), plasma membrane (GO:0005886), extrinsic component of membrane (GO:0019898)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
membrane	2
axonogenesis	1
neuron projection guidance	1
GTP binding	1
GDP binding	1
GTPase regulator activity	1
intracellular anatomical structure	1
cell periphery	1

Protein interactions and networks

STRING

470 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KIAA1755	SYT10	Q6XYQ8	542
KIAA1755	C11orf71	Q6IPW1	496
KIAA1755	SLC35F1	Q5T1Q4	490
KIAA1755	RWDD2A	Q9UIY3	485
KIAA1755	RANBP3L	Q86VV4	474
KIAA1755	EPB41L4A	Q9HCS5	459
KIAA1755	ITM2C	Q9NQX7	454
KIAA1755	CCDC141	Q6ZP82	451
KIAA1755	SLC6A7	Q99884	447
KIAA1755	EML6	Q6ZMW3	446
KIAA1755	ZNF471	Q9BX82	446
KIAA1755	ARHGAP40	Q5TG30	442
KIAA1755	ZBTB47	Q9UFB7	436
KIAA1755	VSTM2L	Q96N03	431
KIAA1755	GNG11	P50152	426

IntAct

2 interactions, top by confidence:

A	B	Type	Score
EPHA4	KIAA1755	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (1): RPS4X (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A1L3T7, D4A929, O15049, O94812, P0C7N4, P58660, P97680, Q17Q97, Q1LU99, Q3LUD3, Q3UPH7, Q3UYR4, Q400C9, Q4FZU8, Q562E7, Q571B6, Q58EX7, Q5EB20, Q5JYT7, Q5ND29, Q5ND34, Q5PQS0, Q5XIS1, Q68FE6, Q6PGG2, Q6ZQ12, Q6ZVH7, Q7TNF8, Q7TSI1, Q7Z3H0, Q80U16, Q8BWG4, Q8BXP5, Q8BYG0, Q8C7U1, Q8CB62, Q8CE13, Q8K1S6, Q8K330, Q8N137

Diamond homologs: Q3UPH7, Q58EX7, Q5JYT7, Q8BWG4, Q8TER5, A1L390, A2CG49, E2RP94, F1M0Z1, M0R4F8, O60229, O75962, P10911, P97924, Q0KL02, Q13009, Q1LUA6, Q4VAC9, Q60610, Q63406, Q64096, Q6KAU7, Q6P720, Q6TXD4, Q6XZF7, Q86VW2, Q96PX9, Q9CWR0, Q9H7P9, Q9ULL1, O43307, Q3UTH8, Q58DL7, Q5RDK0, Q7TNR9, Q9QX73

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

218 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	180
Likely benign	23
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

3314 predictions. Top by Δscore:

Variant	Effect	Δscore
20:38213739:GTCAT:G	acceptor_gain	1.0000
20:38213740:TCAT:T	acceptor_gain	1.0000
20:38213741:CAT:C	acceptor_gain	1.0000
20:38213741:CATC:C	acceptor_gain	1.0000
20:38213742:AT:A	acceptor_gain	1.0000
20:38213744:C:CC	acceptor_gain	1.0000
20:38213744:C:T	acceptor_loss	1.0000
20:38213745:T:A	acceptor_loss	1.0000
20:38217251:AC:A	donor_gain	1.0000
20:38217252:CC:C	donor_gain	1.0000
20:38217252:CCCT:C	donor_gain	1.0000
20:38218194:ACGC:A	donor_gain	1.0000
20:38218195:CGCC:C	donor_gain	1.0000
20:38218197:C:CA	donor_gain	1.0000
20:38218202:T:A	donor_gain	1.0000
20:38218216:T:TA	donor_gain	1.0000
20:38218242:A:AC	donor_gain	1.0000
20:38218243:C:CC	donor_gain	1.0000
20:38223634:CTT:C	acceptor_gain	1.0000
20:38225682:A:AC	donor_gain	1.0000
20:38225683:C:CC	donor_gain	1.0000
20:38228142:CTCA:C	donor_loss	1.0000
20:38228144:CA:C	donor_loss	1.0000
20:38228241:C:CC	acceptor_gain	1.0000
20:38239569:AGAG:A	donor_gain	1.0000
20:38239569:AGAGC:A	donor_gain	1.0000
20:38239589:AGGC:A	donor_gain	1.0000
20:38245928:CA:C	donor_gain	1.0000
20:38213753:A:T	acceptor_gain	0.9900
20:38217246:GGCTC:G	donor_loss	0.9900

AlphaMissense

7731 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:38241599:A:G	W178R	0.993
20:38241599:A:T	W178R	0.993
20:38241893:A:G	W80R	0.993
20:38241893:A:T	W80R	0.993
20:38241891:C:A	W80C	0.991
20:38241891:C:G	W80C	0.991
20:38241816:G:C	F105L	0.990
20:38241816:G:T	F105L	0.990
20:38241818:A:G	F105L	0.990
20:38241597:C:A	W178C	0.987
20:38241597:C:G	W178C	0.987
20:38241696:G:C	F145L	0.987
20:38241696:G:T	F145L	0.987
20:38241697:A:G	F145S	0.987
20:38241698:A:G	F145L	0.987
20:38245977:G:C	F51L	0.987
20:38245977:G:T	F51L	0.987
20:38245979:A:G	F51L	0.987
20:38241817:A:G	F105S	0.984
20:38241686:A:G	W149R	0.983
20:38241686:A:T	W149R	0.983
20:38213618:G:C	F1009L	0.981
20:38213618:G:T	F1009L	0.981
20:38213620:A:G	F1009L	0.981
20:38217299:C:G	R952P	0.981
20:38241862:A:T	V90D	0.981
20:38245966:G:T	A55D	0.980
20:38246078:A:C	Y18D	0.980
20:38241573:A:C	F186L	0.979
20:38241573:A:T	F186L	0.979

dbSNP variants (sampled 300 via entrez): RS1000037098 (20:38258839 C>G), RS1000076789 (20:38212021 A>T), RS1000279994 (20:38229223 G>A), RS1000325566 (20:38247367 C>T), RS1000333984 (20:38241396 A>G,T), RS1000345353 (20:38247720 C>G), RS1000389149 (20:38247700 T>C), RS1000439207 (20:38234817 C>T), RS1000452734 (20:38219502 A>C), RS1000459932 (20:38259765 C>G), RS1000518797 (20:38254130 C>A), RS1000538033 (20:38214202 C>T), RS1000590255 (20:38253000 C>A,G), RS1000647312 (20:38248701 T>C), RS1000683935 (20:38210834 G>A,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

33 associations (top):

Study	Trait	p-value
GCST001969_12	Heart rate	5.000000e-29
GCST003818_73	Resting heart rate	7.000000e-72
GCST003943_4	Hepcidin levels	2.000000e-07
GCST003992_33	Photic sneeze reflex	3.000000e-31
GCST004733_10	Heart rate variability traits (RMSSD)	5.000000e-06
GCST004733_19	Heart rate variability traits (RMSSD)	1.000000e-08
GCST004734_22	Heart rate variability traits (SDNN)	3.000000e-06
GCST005789_30	Resting heart rate	3.000000e-28
GCST006629_23	Pulse pressure	3.000000e-11
GCST007217_6	RR interval (heart rate)	9.000000e-09
GCST007269_1	Pulse pressure	5.000000e-08
GCST010320_141	PR interval	4.000000e-12
GCST010321_93	PR interval	7.000000e-12
GCST010703_294	Brain morphology (MOSTest)	1.000000e-14
GCST010796_1876	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-17
GCST010796_1877	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-17
GCST010796_1878	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-12
GCST010796_1879	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-12
GCST010796_1880	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-10
GCST010796_1881	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-10
GCST010796_1882	Electrocardiogram morphology (amplitude at temporal datapoints)	6.000000e-09
GCST010796_1883	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST010796_1916	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-19
GCST010796_1917	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-19
GCST010796_1918	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-11
GCST010796_1919	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-16
GCST010796_1920	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-09
GCST010796_1921	Electrocardiogram morphology (amplitude at temporal datapoints)	7.000000e-11
GCST010796_1922	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-15
GCST010796_1923	Electrocardiogram morphology (amplitude at temporal datapoints)	6.000000e-15

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0007887	autosomal dominant compelling helio-ophthalmic outburst syndrome
EFO:0008003	heart rate variability measurement
EFO:0005763	pulse pressure measurement
EFO:0004831	RR interval
EFO:0004462	PR interval
EFO:0004346	neuroimaging measurement
EFO:0004327	electrocardiography
EFO:0004531	urate measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, increases expression	3
Panobinostat	affects cotreatment, increases expression	2
sotorasib	decreases expression, affects cotreatment	1
bisphenol A	increases expression	1
sodium arsenite	increases expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
2,2’,4,4’,5-brominated diphenyl ether	decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
trametinib	affects cotreatment, decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Vorinostat	affects cotreatment, increases expression	1
Arsenic	increases methylation	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer